UB Paderborn / Katalog / Suche / in CDI

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors

Oncogene, 2014-03, Vol.33 (12), p.1590-1600

2014

Link zum Volltext

Verfügbarkeit prüfen

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates

Annals of oncology, 2013-07, Vol.24 (7), p.1900-1907

2013

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of axitinib in advanced neuroendocrine tumors

Endocrine-related cancer, 2016-05, Vol.23 (5), p.411-418

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer

British journal of cancer, 2013-10, Vol.109 (7), p.1725-1734

2013

Link zum Volltext

Verfügbarkeit prüfen

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Annals of oncology, 2018-10, Vol.29, p.viii467-viii468

2018

Link zum Volltext

Verfügbarkeit prüfen

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

British journal of cancer, 2005-07, Vol.93 (2), p.195-199

2005

Link zum Volltext

Verfügbarkeit prüfen

Transcatheter pulmonic valve replacement in carcinoid heart disease

European heart journal cardiovascular imaging, 2015-09, Vol.16 (9), p.1046-1046

2015

Link zum Volltext

Verfügbarkeit prüfen

The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET)

Annals of oncology, 2018-10, Vol.29, p.viii473-viii473

2018

Link zum Volltext

Verfügbarkeit prüfen

Maximizing the Potential of Bevacizumab in Cancer Treatment

The oncologist (Dayton, Ohio), 2004-06, Vol.9 (S1), p.36-42

2004

Link zum Volltext

Verfügbarkeit prüfen

Molecular mechanisms underlying the development of hepatocellular carcinoma

Seminars in oncology, 2001-10, Vol.28 (5), p.521-531

Bergsland, Emily K

2001

Link zum Volltext

Verfügbarkeit prüfen

37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial)

European journal of cancer (1990), 2015-09, Vol.51, p.S728-S728

2015

Link zum Volltext

Verfügbarkeit prüfen

Aggressive Surgical Management Best Serves Patients With Small Intestinal Neuroendocrine Tumors

The Journal of surgical research, 2012, Vol.172 (2), p.195-195

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract No. 137 Post-Procedure Hyponatremia in Patients Undergoing Liver Embolotherapy for Neuroendocrine Tumor Metastases

Journal of vascular and interventional radiology, 2023-03, Vol.34 (3), p.S64-S64

2023

Link zum Volltext

Verfügbarkeit prüfen

Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab

JNCI : Journal of the National Cancer Institute, 2007-08, Vol.99 (16), p.1232-1239

2007

Link zum Volltext

Verfügbarkeit prüfen

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

The Journal of clinical investigation, 2003-05, Vol.111 (9), p.1287-1295

2003

Link zum Volltext

Verfügbarkeit prüfen

Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2005-06, Vol.23 (16), p.3706-3712

2005

Link zum Volltext

Verfügbarkeit prüfen

A Primary Xenograft Model of Pancreatic Neuroendocrine Carcinoma Maintains a Neuroendocrine Tumor Gene Expression Signature

The Journal of surgical research, 2011, Vol.165 (2), p.296-296

2011

Link zum Volltext

Verfügbarkeit prüfen

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

The Journal of clinical investigation, 2000-04, Vol.105 (8), p.1045-1047

2000

Link zum Volltext

Verfügbarkeit prüfen

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide

Endocrine-related cancer, 2014-10, Vol.21 (5), p.705-714

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2003-01, Vol.21 (1), p.60-65

2003

Link zum Volltext

Verfügbarkeit prüfen

Reduced GFI1 Transcription Factor Expression in Small Intestinal Neuroendocrine Tumor Metastases

The Journal of surgical research, 2010, Vol.158 (2), p.266-267

2010

Link zum Volltext

Verfügbarkeit prüfen

Lack of NKX2.2 Transcription Factor Expression Distinguishes Bronchopulmonary Typical Carcinoids from Gastrointestinal Neuroendocrine Tumors

The Journal of surgical research, 2010, Vol.158 (2), p.267-267

2010

Link zum Volltext

Verfügbarkeit prüfen

QS138. The FEV Transcription Factor is Abberantly Expressed in Neuroendocrine Tumors of the Small Intestine

The Journal of surgical research, 2009, Vol.151 (2), p.288-288

2009

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS213-TPS213

2010

Link zum Volltext

Verfügbarkeit prüfen

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome

Neuroendocrinology, 2018, Vol.106 (Supplement: 1), p.224

2018

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates

A phase II study of axitinib in advanced neuroendocrine tumors

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

Transcatheter pulmonic valve replacement in carcinoid heart disease

The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET)

Maximizing the Potential of Bevacizumab in Cancer Treatment

Molecular mechanisms underlying the development of hepatocellular carcinoma

37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial)

Aggressive Surgical Management Best Serves Patients With Small Intestinal Neuroendocrine Tumors

Abstract No. 137 Post-Procedure Hyponatremia in Patients Undergoing Liver Embolotherapy for Neuroendocrine Tumor Metastases

Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer

A Primary Xenograft Model of Pancreatic Neuroendocrine Carcinoma Maintains a Neuroendocrine Tumor Gene Expression Signature

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide

Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

Reduced GFI1 Transcription Factor Expression in Small Intestinal Neuroendocrine Tumor Metastases

Lack of NKX2.2 Transcription Factor Expression Distinguishes Bronchopulmonary Typical Carcinoids from Gastrointestinal Neuroendocrine Tumors

QS138. The FEV Transcription Factor is Abberantly Expressed in Neuroendocrine Tumors of the Small Intestine

A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC)

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome

Suchergebnisse filtern